Pure Bioscience Stock Analysis
| PURE Stock | USD 0.05 0 7.00% |
Pure Bioscience holds a debt-to-equity ratio of 0.087. Pure Bioscience's financial risk is the risk to Pure Bioscience stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Pure Bioscience's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Pure Bioscience's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Pure OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Pure Bioscience's stakeholders.
For most companies, including Pure Bioscience, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Pure Bioscience, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Pure Bioscience's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Pure Bioscience's debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Pure Bioscience is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Pure Bioscience to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Pure Bioscience is said to be less leveraged. If creditors hold a majority of Pure Bioscience's assets, the OTC Stock is said to be highly leveraged.
Pure Bioscience is overvalued with Real Value of 0.0413 and Hype Value of 0.05. The main objective of Pure Bioscience otc analysis is to determine its intrinsic value, which is an estimate of what Pure Bioscience is worth, separate from its market price. There are two main types of Pure Bioscience's stock analysis: fundamental analysis and technical analysis.
The Pure Bioscience otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Pure Bioscience's ongoing operational relationships across important fundamental and technical indicators.
Pure |
Pure OTC Stock Analysis Notes
About 41.0% of the company outstanding shares are owned by corporate insiders. The book value of Pure Bioscience was at this time reported as 0.03. The company recorded a loss per share of 0.04. Pure Bioscience had not issued any dividends in recent years. The entity had 1:8 split on the 15th of August 2012. PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.The quote for Pure Bioscience is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Pure Bioscience contact Tom CPA at 619 596 8600 or learn more at https://www.purebio.com.Pure Bioscience Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Pure Bioscience's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Pure Bioscience or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Pure Bioscience generated a negative expected return over the last 90 days | |
| Pure Bioscience has high historical volatility and very poor performance | |
| Pure Bioscience has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders |
Pure Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pure Bioscience's market, we take the total number of its shares issued and multiply it by Pure Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Pure Profitablity
Pure Bioscience's profitability indicators refer to fundamental financial ratios that showcase Pure Bioscience's ability to generate income relative to its revenue or operating costs. If, let's say, Pure Bioscience is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Pure Bioscience's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Pure Bioscience's profitability requires more research than a typical breakdown of Pure Bioscience's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.98) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.98. Technical Drivers
As of the 1st of February, Pure Bioscience holds the Coefficient Of Variation of (1,549), variance of 62.81, and Risk Adjusted Performance of (0.04). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pure Bioscience, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Pure Bioscience, which can be compared to its competitors. Please check Pure Bioscience risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Pure Bioscience is priced some-what accurately, providing market reflects its current price of 0.0465 per share. As Pure Bioscience appears to be a penny stock we also advise to check out its jensen alpha numbers.Pure Bioscience Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Pure Bioscience price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Pure Bioscience Outstanding Bonds
Pure Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pure Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pure bonds can be classified according to their maturity, which is the date when Pure Bioscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Pure Bioscience Predictive Daily Indicators
Pure Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pure Bioscience otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pure Bioscience Forecast Models
Pure Bioscience's time-series forecasting models are one of many Pure Bioscience's otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pure Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Pure Bioscience Debt to Cash Allocation
Many companies such as Pure Bioscience, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Pure Bioscience currently holds 239 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Pure Bioscience has a current ratio of 1.98, which is within standard range for the sector. Debt can assist Pure Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Pure Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pure Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pure to invest in growth at high rates of return. When we think about Pure Bioscience's use of debt, we should always consider it together with cash and equity.Pure Bioscience Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Pure Bioscience's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Pure Bioscience, which in turn will lower the firm's financial flexibility.Pure Bioscience Corporate Bonds Issued
Most Pure bonds can be classified according to their maturity, which is the date when Pure Bioscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Pure OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Pure Bioscience prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pure shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Pure Bioscience. By using and applying Pure OTC Stock analysis, traders can create a robust methodology for identifying Pure entry and exit points for their positions.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Pure Bioscience to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Complementary Tools for Pure OTC Stock analysis
When running Pure Bioscience's price analysis, check to measure Pure Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pure Bioscience is operating at the current time. Most of Pure Bioscience's value examination focuses on studying past and present price action to predict the probability of Pure Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pure Bioscience's price. Additionally, you may evaluate how the addition of Pure Bioscience to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |